Investigating the Effect of Micardis® on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients

This study is currently recruiting participants.

Verified by Boehringer Ingelheim Pharmaceuticals, January 2010

First Received: April 9, 2009 Last Updated: January 13, 2010 History of Changes

Sponsor:	Boehringer Ingelheim Pharmaceuticals
Information provided by:	Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00879411

Purpose

Practical experience report (PER) investigating the effect of Micardis® on the average 24h blood pressure of therapy-naive and therapy-experienced patients

Condition	Intervention
Hypertension	Drug: telmisartan

Study Type:	Observational
Study Design:	Case-Only, Prospective
Official Title:	24h BP Under Micardis in Daily Practice

Resource links provided by NLM:

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Telmisartan

U.S. FDA Resources

Further study details as provided by Boehringer Ingelheim Pharmaceuticals:

Primary Outcome Measures:

collect significant data on powerful BP reduction of Telmisartan in the context of 24h BP reduction after a 6 to 8 week treatment period [ Time Frame: 8 weeks ]

Secondary Outcome Measures:

drug safety, efficacy and tolerability of Telmisartan [ Time Frame: 8 weeks ]

Estimated Enrollment:	1000
Study Start Date:	April 2009
Estimated Primary Completion Date:	October 2009 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years to 95 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

hypertensive patients

Criteria

Inclusion Criteria:

Patients who have recently been diagnosed with hypertension
Patients whose current blood pressure treatment are inadequate and needs to be revised are suitable for inclusion.

Exclusion Criteria:

- None (according to investigator)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00879411

Contacts

Contact: Boehringer Ingelheim Study Coordinator

1-800-243-0127

clintriage.rdg@boehringer-ingelheim.com

Show 111 Study Locations

Sponsors and Collaborators

Boehringer Ingelheim Pharmaceuticals

Investigators

Study Chair:

Boehringer Ingelheim

Boehringer Ingelheim Pharmaceuticals

More Information

No publications provided

Responsible Party:	Boehringer Ingelheim ( Boehringer Ingelheim, Study Chair )
Study ID Numbers:	502.582
Study First Received:	April 9, 2009
Last Updated:	January 13, 2010
ClinicalTrials.gov Identifier:	NCT00879411 History of Changes
Health Authority:	Switzerland: Laws and standards

Additional relevant MeSH terms:

Angiotensin II Type 1 Receptor Blockers
Molecular Mechanisms of Pharmacological Action
Vascular Diseases
Angiotensin-Converting Enzyme Inhibitors
Enzyme Inhibitors

Cardiovascular Diseases
Telmisartan
Pharmacologic Actions
Protease Inhibitors
Hypertension

ClinicalTrials.gov processed this record on February 08, 2010